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Background: Human papillomavirus (HPV) is the aetiological agent for cervical cancer and genital warts.
Concurrent HPV and HIV infection in the South African population is high. HIV positive (+) women are often
infected with multiple, rare and undetermined HPV types. Data on HPV incidence and genotype distribution are
based on commercial HPV detection kits, but these kits may not detect all HPV types in HIV +women. The
objectives of this study were to (i) identify the HPV types not detected by commercial genotyping kits present in a
cervical specimen from an HIV positive South African woman using next generation sequencing, and (ii) determine
if these types were prevalent in a cohort of HIV-infected South African women.
Methods: Total DNA was isolated from 109 cervical specimens from South African HIV +women. A specimen
within this cohort representing a complex multiple HPV infection, with 12 HPV genotypes detected by the Roche
Linear Array HPV genotyping (LA) kit, was selected for next generation sequencing analysis. All HPV types present in
this cervical specimen were identified by Illumina sequencing of the extracted DNA following rolling circle
amplification. The prevalence of the HPV types identified by sequencing, but not included in the Roche LA, was
then determined in the 109 HIV positive South African women by type-specific PCR.
Results: Illumina sequencing identified a total of 16 HPV genotypes in the selected specimen, with four genotypes
(HPV-30, 74, 86 and 90) not included in the commercial kit. The prevalence’s of HPV-30, 74, 86 and 90 in 109 HIV
positive South African women were found to be 14.6%, 12.8%, 4.6% and 8.3% respectively.
Conclusions: Our results indicate that there are HPV types, with substantial prevalence, in HIV positive women not
being detected in molecular epidemiology studies using commercial kits. The significance of these types in relation
to cervical disease remains to be investigated.
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Worldwide, cervical cancer is the third most common
cancer in women, with 86% of cases and 88% of deaths
occurring in developing countries [1]. In South Africa
the incidence of HPV infection is high [2] resulting in
cervical cancer being the leading cause of cancer-related
death in women [1].
It has been conclusively established that infection with
specific high-risk human papillomaviruses (HPV) is
causally linked to the development of cervical cancer [3].
Other types of HPV are also aetiologically associated
with anogenital warts [4]. Papillomaviruses (family Papil-
lomaviridae) are small DNA viruses with double-
stranded circular genomes that infect the cutaneous and
mucosal epithelia. More than 200 different HPV types
have been identified, with viruses in a type sharing
greater than 90% sequence identity in the L1 major cap-
sid gene [5]. To date, full genome sequences are avail-
able for 118 HPV types. At least 40 HPV types infect the
anogenital mucosa, with 12 of these classified by the
International Agency for Research on Cancer (IARC) as
carcinogenic to humans (Group 1), one as probably car-
cinogenic (Group 2A) and 12 as possibly carcinogenic
(Group 2B) [6]. HPV-16 and HPV-18 are generally
recognized as the most important oncogenic viruses,
present in about 71% of cervical cancer cases worldwide
[7]. However, several studies (for example [2,8,9]) have
found significant variation in the regional contribution
of HPV types to cervical cancer. Additionally, the largest
worldwide HPV genotype distribution study carried out
to date showed that the highest proportion of multiple
HPV infections and infection with undetermined HPV
types and species occurs in Africa [7]. Data on HPVs
that are regionally prevalent are crucial in determining
the risks associated with particular HPV types, and in
informing vaccine strategies in the region. There is lim-
ited information of this kind available for South Africa.
South Africa is also faced with one of the worst
Human immunodeficiency virus (HIV) epidemics in the
world, with an estimated 5.63 million infected people
and a higher HIV prevalence in women than men [10].
Consequently, the frequency of concurrent HPV and
HIV infection is high [11-13]. HIV positive women are
at an increased risk for the development of cervical dis-
ease [11]. These women have higher HPV viral loads,
higher viral persistence and infection with rare and un-
determined types [13,14]. Further epidemiological data
for these types is required to estimate their potential
oncogenic risk. HIV positive women also have a high in-
cidence of multiple infections [14], with an observed fre-
quency of between 50 to 80% [13,15,16]. In HIV
negative populations the observed frequency is less, al-
though higher than previously thought, at between 24.8
to 62.6% [17]. The elevated incidence of multiple HPVinfections in HIV+women raises concerns over possible
recombination between different genotypes and the
emergence of novel pathogenic types. For example, Jiang
et al., [18] recently demonstrated intratypic recombin-
ation between HPV-16 variants in a natural coinfection
involving eight HPV-16 types.
Molecular diagnostic tools for HPV DNA detection in
clinical samples must be able to accurately detect and
genotype the specific HPV types circulating in a par-
ticular population. The majority of HPV DNA detection
kits are PCR-based, targeted to known HPV types and
generally to those prevalent in the developed world.
These tests are therefore not suitable for the detection
of rare or novel HPV types. PCR-based assays using
consensus primers are, additionally, often not able to
reliably detect all the HPV types involved in multiple
infections [19-21], as commonly seen in HIV infected
individuals.
The recent emergence of next-generation sequencing
(NGS) technologies has opened up the opportunity to
directly examine viral diversity in clinical specimens, with-
out prior sequence information (reviewed in [22]. In this
study we investigated the use of Illumina sequencing (se-
quencing by synthesis technology, http://www.illumina.
com/systems/genome_analyzer_iix/technology.ilmn) to de-
tect and genotype the HPV types present in a complex
multiple infection in a cervical specimen from an HIV-
infected South African woman. The HPV types detected
using Illumina sequencing were compared to those
detected by the Roche Linear Array HPV genotyping (LA)
test on the same specimen. The prevalence of the HPV
types present, but not included in the commercial kit, was
also determined by type-specific PCR in the cohort of 109
HIV-infected South African women described by Moodley
and co-workers [13].
Results
Roche LA testing of specimen number HH015 from our
study population identified 12 HPV types. As this speci-
men contained an extremely complex population of
closely and distantly related HPV types it was selected
for next-generation sequencing. Total DNA was
extracted from specimen HH015 and, prior to sequen-
cing, the HPV circular DNA present was enriched using
a randomly primed rolling circle amplification (RCA)
method.
Illumina sequencing and analysis pipeline
The enriched DNA sample was sequenced using the
Illumina GAII system as outlined in the Methods. A
total of 9818116 reads of 76 nt in length were obtained.
These short sequence reads (SSRs) were trimmed to 41
nt resulting in reads with an average quality score of 31.
An analysis pipeline was designed for the detection of
Figure 1 Schematic representation of the pipeline designed for
the analysis of the Illumina reads and detection of HPV
genotypes present.
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Briefly, to analyze the ability to assemble full HPV gen-
ome sequences from the SSR data, the reads were de
novo assembled. The assembled contiguous sequences
were then classified based on the top BLAST hits to
NCBI databases. HPV sequences identified within the
databases were then downloaded and used as reference
sequences for mapping of the SSRs. This was done to es-
timate the percentage of genomes sequenced and cover-
age of all the HPV types present.Full HPV genome assembly
The trimmed SSRs were de novo assembled using Velvet
[23] and CLC Genomics Workbench. More complete or
near complete HPV genomes were assembled with Vel-
vet than with CLC Genomics Workbench and Velvet
was therefore used for all subsequent assemblies (results
not shown). De novo assembly resulted in four contigs
that represent full length HPV genomes, with top
BLAST hits to HPV types 39, 40, 16, and 56 (Table 1).Table 1 BLASTN results for Velvet de novo assembled
contigs*
HPV
type
Number of
contigs
Coverage Region Genbank
accession top hit
(Identity; E-value)
39 1 7466.9 Full length M62849 (99;0.0)
40 1 1391.8 Full length X74478 (99; 0.0)
16 1 1011.2 Full length FJ610149 (99;0.0)
56 1 93.9 Full length EF177179 (99;0.0)
30 2 43.3 5990-3276 X74474 (98; 0.0)
49.2 3249-5302 X74474 (98; 0.0)
*Only contigs representing full or near full length genomes with a top BLASTN
hit to HPV sequences are presented.The coverage (or average number of times each base
was sequenced) of these contigs ranged from 7466.9 for
HPV-39 to 93.9 for HPV-56. A further two contigs had
top BLAST hits to HPV-30 (Table 1), and together rep-
resent the complete genome (> 90%), excluding the re-
gion from bases 5302 to 5990 within the HPV-30 L2
gene. The remaining HPV types present, but not fully
assembled, were identified by using all the assembled
contigs greater than 100 bp in BLASTN and BLASTX
searches of the NCBI databases. The HPV genome
sequences identified in the BLAST searches were down-
loaded from the NCBI database and used as reference
sequences for read mapping.
Read mapping analysis of HPV genotypes in HH015
Initially, any reads representing host DNA were excluded
by mapping the SSRs to a human genome reference
sequence. A total of 6 337 064 reads (64.5% of the total
reads, Figure 2) were mapped to the human genome and
excluded from subsequent analyses.
Reads excluding human DNA sequences were then
mapped to the HPV reference sequences. A total of 2
022 368 reads (20.6% of total reads) were mapped to
HPV genome sequences and 1 458 684 reads (14.9%)
could not be mapped to human or HPV DNA sequences
(Figure 2). Individual mapping to the HPV reference
genomes identified HPV types 39, 40, 16, 70, 74, 56, 30,
45, 59, 71, 35, 55, 90, 53, 86, 81, and 84, in order of
highest to lowest sequencing coverage (Table 2, individ-
ual mapping). HPV type 39 had the highest coverage
(7604.5) and clearly represented the dominant type in
the specimen. HPV types 40, 16, 70, 74, 56 and 30 had
high coverage, ranging from 1384.5 for HPV-40 to 45.9
for HPV-30. Coverage greater than 10 was obtained for
HPV types 45, 71 and 55, while the coverage for HPV
types 59, 90, 35, 86, 53 and 81 ranged from 7.6 to 2.2.
The percentage of the genome sequenced ranged from
100 to 88.6% for 12 of the HPV types identified (39, 40,
16, 70, 74, 56, 30, 45, 71, 59, 90 and 35) and from 77.9
to 51.8% for HPV types 55, 86, 53 and 81. The coverage
for HPV-84 was low (1.9) and only 7.9% of the reference
HPV-84 genome was sequenced.
The reference mapping to the HPV genomes was
additionally performed using all the reference genome
sequences in a single mapping (Table 2, simultaneous
mapping), with random assignment of reads mapping
to more than one genome. The coverage for types 39,
40, 16, 74, 56, 30, 71, 90, 86 and 81 remained equal or
close to that observed when reads were mapped to the
respective genomes individually. The coverage for
HPV-70, 45, 55, 59, 53 and 35, however decreased sig-
nificantly (underlined in Table 2) when mapped simul-
taneously. The coverage of HPV-70, for example
decreased tenfold from 171 to 17. Although the
Figure 2 Pie chart summary of mapping of Illumina reads from specimen HH015 to human and HPV reference sequences using CLC
Genomics Workbench 4.6.1 (Global alignment, mismatch cost 2, limit 5). Numbers on the pie chart on the right indicate HPV genotypes.
The Genbank accession numbers for the sequences used as references in the mappings are given in Table 2.
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ence in coverage is probably due to regions within
these types having high sequence identity to regions
within other HPV types present in the sample, such asTable 2 Mapping of Illumina reads generated for specimen H
HPV
type
Genbank accession of
reference sequence
Individual mapping
Read
count€
Coverage# Pe
geno
39* M62849 1452838 7604.5
40* X74478 267072 1384.5
16* FJ610149 204214 1059.0
70* HPU21941 32187 171.0
74 AF436130 27099 142.7
56 EF177179 18510 97.4
30 X74474 8781 45.9
45* EF202160 2873 15.9
71* NC002644 2106 10.8
55* HPU31791 1400 14.2
59* X77858 1342 7.6
90 AY057438 1136 5.9
35 PPH35CG 1109 6.5
86 AF349909 683 5.3
53* NC001593 682 4.6
81* AJ620209 308 2.2
84* AF293960 28 1.9
* HPV types detected by the Roche Linear Array HPV Genotyping kit.
€ Number of reads mapped to the reference.
#Average number of times each base was sequenced.parts of the region coding for the conserved L1 pro-
tein. Based on alignment of the E1-E2 and L1 genes,
HPV types 70, 45 and 59 cluster with HPV-39 in the
alpha-7 PV genus, HPV-55 clusters with HPV-74 in theH015 to HPV reference genome sequences
Simultaneous mapping
rcentage of
me sequenced
Read
count€
Coverage# Percentage of
genome sequenced
100.0 1450445 7592.9 100.0
100.0 267072 1384.5 100.0
100.0 204212 1059.0 100.0
97.6 3295 17.1 97.6
98.7 26802 139.3 98.7
100.0 18409 96.9 100.0
99.9 8612 45.0 99.9
94.7 774 4.0 94.4
99.6 2088 10.7 99.6
51.8 587 3.1 49.2
91.2 692 3.6 91.2
98.0 1116 5.7 98.0
88.6 720 3.8 88.4
66.0 680 5.3 66.0
77.9 462 2.4 77.6
72.5 308 2.2 72.5
7.6 11 0.1 4.7
Table 3 Mapping of Illumina reads generated for specimen HH015 to HPV long control region (LCR) sequences
HPV
type
Genbank accession of
reference sequence
Individual mapping Simultaneous mapping
Read
count€
Coverage# Percentage of
LCR sequenced
Identity° Read
count€
Coverage# Percentage of
LCR sequenced
Identity°
39* M62849 131419 6916.8 100 100 131417 6916.7 100 100
16* FJ610149 20258 998.3 100 99.8 20258 998.3 100 99.8
40* X74478 19984 1147.5 100 99.6 19984 1147.5 100 99.6
56 EF177179 1940 100.2 100 99.6 1940 100.2 100 99.6
74 AF436130 1565 91.9 88.6 97.9 1560 91.6 88.6 97.9
30 X74474 789 40.9 99.2 99.2 789 40.9 99.2 99.2
71* NC002644 176 10.0 92.9 100 176 10.0 92.9 100
70* HPU21941 97 4.7 93.6 99.9 95 4.6 93.6 99.9
35 PPH35CG 79 4.4 84.8 99.6 79 4.4 84.8 99.6
45* EF202160 68 3.7 92.5 98.9 68 3.7 92.5 98.9
59* X77858 57 3.4 83.6 100 57 3.4 83.6 100
90 AY057438 55 3.6 87.4 98.6 55 3.6 87.4 98.6
55* HPU31791 54 5.7 53.3 98.7 18 2.0 50.0 98.7
86 AF349909 50 4.6 55.0 98.0 50 4.6 55.0 98.0
81* AJ620209 29 2.4 61.8 100 29 2.4 61.8 100
53* NC001593 24 2.7 45.7 98.6 24 2.7 45.7 98.6
* HPV types detected by the Roche Linear Array HPV Genotyping kit.
€ Number of reads mapped to the reference sequence using CLC Genomics Workbench 4.6.1 (limit 3, cost 2, global alignment).
# Average number of times each base was sequenced.
° Percentage identity of the assembled contig to the reference sequence.
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HPV-53 with HPV-30 in alpha-6 [24]. As regions of
high identity may lead to the possibility of over- or
under-representation of an HPV type, we tested the
mapping of the SSRs to a sub-genomic region that is
highly variable between the HPV genomes, the long
control region (LCR; Table 3).
The SSRs were mapped to the LCR of the HPV types
individually and in a single simultaneous assembly
(Table 3). A high consistency was found between the
two mappings for all HPV types (Table 3), with equal or
near equal read counts, coverage and percentage of the
LCR sequenced for all HPV types in both mappings. TheTable 4 Type-specific primers for the detection of HPV types
HPV type Primer name Sequence
30 HPV30F TGAGGTACAAGAAACATCG
HPV30R CGTACGTGATATTCTGTGAA
74 HPV74F1 TGCTGGACAACATGCATGG
HPV74R1 CCTCTGTACCTGTATTTTCC
86 HPV86F GTTTGTAGGAGTGTGGCATC
HPV86R TTGTACTGCCAAGTTTCTGT
90 HPV90E6F GCGGAACAGCATTAACAGA
HPV90E6R TAAGCCGTTCCTTTTCCTCA
aPosition of primers within the E6 gene of HPV 30 (X74474), bHPV 86 (AF349909) an
dPosition of primers in the E6 and E7 genes of HPV 74 AE10 subtype (AF436130).coverage obtained in these mappings is then probably a
more accurate representation of the relative prevalence
of each HPV type in the sequenced sample. The cover-
age of HPV types 39, 16, 40, 56, 74 and 30 was high and
ranged from 6918.8 to 40.9. HPV-71 had a lower cover-
age of 10 and coverage of types 70, 35, 45, 59, 90, 55, 86,
81 and 53 was the lowest from 4.7 to 2.7.No reads were
found to map to the HPV-84 LCR. The percentage of
the LCR sequenced ranged from 100 to 83.6% for HPV
types 39, 16, 40, 56, 74, 30, 71, 70, 35, 45, 59, 90 and was
lower (61.8 to 45.7%) for HPV types 55, 86, 81 and 53.
This is comparable to that observed for the reference
mapping to the complete genomes.30, 74, 86 and 90
Target Amplicon size (bp)
TTGC 158-180a 346
ACC 503-481a
AAAAATCCTAC 418-448 d 328
GCCATGT 745-719 d
C 29-10b 236
CC 7781-7802b
GGA 95-116 c 258
CT 352-331 c
d cHPV 90 (AY057438).
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Workbench and MAQ, but the results found not to dif-
fer significantly (results not shown). The reference map-
pings reported here were performed with CLC
Genomics Workbench (Tables 2 and 3).
Prevalence of HPV types 30, 74, 86 and 90 in study
population
To confirm the presence of the additional types detected
by Illumina sequencing we designed type-specific pri-
mers targeting the E6/E7 genes of HPV-30, -74, -86 and
−90 (Table 4). BLASTN searches of the nt database, with
the primers as query, confirmed their type-specificity.
PCR amplification using these primer sets, with DNA
extracted from specimen HH015 as template, resulted in
amplicons of the expected sizes (Figure 3). The PCR
products were sequenced and the presence of all four
types confirmed in the HH015DNA. The prevalence of
HPV types 30, 74, 86 and 90 in the cohort of 109 HIV
positive South African women was then determined by
PCR (Figure 3) using the type-specific primers, and
found to be 14.6%, 12.8%, 4.6% and 8.3%, respectively.Figure 3 Representative agarose gel analyses following PCR amplifica
types 30 (A), 74 (B), 86 (C) and 90 (D) from clinical specimens. A nega
from HH015 (Positive) were included.Discussion
Several studies have indicated that many current HPV
typing methods are not able to reliably identify all types
present in complex multiple infections [19,21]. In the
WHO HPV LabNet Global genotyping proficiency study
most labs (90%) were able to identify HPV-16 and 18 as
individual types but less than 80% were able to identify
HPV 56, 59, and 68. Of more concern was that 28/84
data sets reported false positive results. A notable de-
crease was observed in the performance of most assays
in identifying types when present in multiple infections
and only 50 to 73% of the data sets generated by these
assays correctly detected the types present [19]. This
suggests the need for further assessment of the tests
used and regular participation in proficiency testing to
ensure the quality of data. It also suggests that epidemio-
logical data may not be completely accurate and result
in detection biases.
Recently a study was published using 454 NGS tech-
nology and HPV specific primers targeting the conserved
L1 gene. A good correlation was reported between
INNO-LiPA HPV Genotyping Extra assay (Innogenetics,tion of a type-specific region within the E6/E7 genes of HPV
tive control with water (Negative) and a positive control using DNA
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sensitivity [25]. This study differs from our NGS study
in that our study does not use specific primers, had a
pre-amplification enrichment step using RCA as well as
using the Illumina GAII system to generate sequence. Of
note was that using this methodology there was a greater
sensitivity than LA genotyping. This study demonstrates
the use of NGS in genome sequencing and genotyping
of the HPV types present in a complex multiple infec-
tion in an unbiased manner. The study design was a
metagenomic-based approach, extracting total DNA
from a cervical specimen (HH015), without prior virus
purification. Circular DNA present in the sample was
enriched using phage phi29 DNA polymerase in a
randomly-primed RCA method [26]. This allowed us to
amplify whole HPV genomes in the sample in an un-
biased sequence-independent manner, unlike other amp-
lification methods such as PCR. This robust technique
has successfully been used for the amplification of a
number of circular DNA viruses (reviewed in [27]), in-
cluding HPV [28], and provides ample quantities of suf-
ficiently pure DNA for sequencing. Illumina sequencing
was chosen based on the expected high depth of cover-
age achieved with this technology.
Approximately 20% of the short sequence reads gener-
ated by Illumina sequencing of the RCA-enriched DNA
from specimen HH015 were identified as HPV sequences
(Figure 2). Considering the small size of the HPV genome
(8Kb), even in relatively high copy numbers, in relation to
the human genome (ca. 3000 Mb), this level of coverage
indicates the highly successful amplification or enrichment
of the HPV DNA by the RCA technique. Complete or
near complete genomes were assembled for five HPV
types (30, 39, 40, 16, 56). Both de novo assembly and refer-
ence mapping identified these types as being the most
abundant in the sample. We were not able to de novo as-
semble full genomes for the less abundant types in the
sample, and instead used reference mapping to identify all
the types present.
As the HH015 sample contains a mixture of HPV
types, reference mapping may be problematic. Short
reads sequenced from one type may map to regions of
high identity in the genomes of other types present. This
could lead to an under or over-estimation of a types’
abundance, or worse, a false positive. This would be par-
ticularly dependent on the presence of other highly
related types. This is well illustrated when comparing
the read count and coverage obtained when we per-
formed read mappings to HPV genomes individually and
simultaneously (Table 2). Visual inspection of the read
coverage for different regions within the genomes
showed unequal read counts. This has, however, been
observed in many genome sequencing projects where
read coverage is known to be influenced by a number offactors. To overcome these problems, we performed
stringent mappings to a highly variable sub-genomic re-
gion, the LCR. A consistent read count was obtained for
each type whether the mapping was performed individu-
ally with a particular HPV type or simultaneously against
all types (Table 3). This then allowed for a greater degree
of confidence in identifying HPV types that were less
abundant. Further support for this, was our finding that
the percentage of the genomes or LCRs sequenced did
not differ significantly when reads were mapped indi-
vidually or simultaneously. The relative coverage
obtained for the HPV types should reflect the relative
viral loads of each type in the specimen. This is assum-
ing that RCA of different types was equally efficient and
did not have any amplification biases. Based on the map-
ping of sequence to the LCR region the type with the
highest copy number was HPV-39 followed by HPV
types 16, 40, 56, 74, 30, 71, 70, 35, 45, 59, 90, 55, 86, 81,
and then finally HPV type 53 as having the lowest copy
number.
Roche LA testing of DNA extracted from HH015
identified 12 HPV types (16, 39, 40, 45, 52, 53, 55, 59,
70, 71, 81 and 84). Illumina sequencing could reliably
detect 16 HPV types (39, 16, 40, 56, 74, 30, 71, 70, 35,
45, 59, 90, 55, 86, 81, 53), based on de novo assembly
and reference mapping to HPV genomes and LCR
sequences. Both Illumina and Roche LA therefore
detected HPV types 39, 16, 40, 45, 53, 55, 59, 70, 71, 74,
81. LA detected HPV-84 and −52 which were not
detected by Illumina sequencing. Illumina sequencing
identified an additional 6 types not detected by LA; HPV
types 30, 35, 56, 74, 86 and 90. The HR types 35 and 56
are included in the LA, while HPV types 30, 74, 86 and
90, are not.
Illumina sequencing covered 88.6% of the complete
HPV-35 genome and approximately 85% of the HPV-35
LCR with 99.6% identity to the reference sequence. No
reads mapping to HPV-52 were identified. In the LA the
probe for HPV-52 can cross-react with HPV-35, -33 and
−58. A separate probe for HPV-35 is included in the LA,
but was negative for HH015. This may be due to a low
viral load in the specimen; however it may also be that
HPV-35 was mistyped as HPV-52 in the LA result. In
the WHO HPV genotyping global proficiency study, LA
testing was found to frequently give false-positive results
for HPV-52. As no reads mapped to the HPV-84 LCR
the presence of this type, detected by LA, could not be
confirmed by Illumina sequencing. A type-specific PCR
using HPV-84 specific primers was unable to detect
HPV-84 in specimen HH015 (results not shown). HPV-
84 may have been mistyped in the Roche LA result.
The HR HPV-56 was identified by Illumina sequencing
as one of the dominant HPV types in HH015. The
complete genome was assembled at a coverage of 93.9
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was not detected by LA: this is probably because the
limit of detection for HPV-56 in the LA is very high.
Eklund et al. [19] report that this type, and HPV-52, are
frequently undetected in many HPV genotyping assays,
including LA, and their prevalence is probably underes-
timated in epidemiological studies. This is especially
when compared to HPV-16 and −18 prevalence’s, for
which most assays have a significantly lower detection
limit.
Illumina sequencing identified several HPV types in
HH015 not included in the LA (HPV types 30, 74, 86
and 90). HPV-30 has been classified as possibly carcino-
genic [6]. While the remaining types are not classified as
HR oncogenic types, we wanted to know the frequency
of these types in our study population to determine if
they were common. HPV-30 (14.6%) and HPV-74
(12.8%) were found to be the third and fourth most
common low risk types in our cohort, after HPV-62
(23.9%) and HPV-70 (15.6%) [13]. The prevalence of
HPV-86 and 90 was 4.6 and 8.3%, respectively. Although
our study population was small (109), the high preva-
lence of HPV-30 and −74 may warrant their inclusion in
future HPV genotyping studies.
Inclusion of HPV types 30, 74, 86 and 90 into our pre-
viously reported HPV prevalence data for this cohort
[13], showed that only 9.2% of the women had no HPV
(10/109), 18.3% had single HPV infection (20/109) and
72.5% had multiple infection (79/109). The high preva-
lence of multiple HPV infection in this cohort (72.5%)
and small sample size limited our ability to assess the
impact of the individual HPV types 30, 74, 86 and 90 on
the cervical cytology results.
Conclusions
In this study we show that the use of RCA and Illumina
sequencing bypasses or reduces many of the problems
associated with PCR-based HPV detection methods, in-
cluding the requirement for prior sequence information,
false positives due to cross-reactivity between types, false
negatives associated with low viral loads, and biased
amplification that makes identifying all the types present
in a multiple infection difficult [19-21]. Many improve-
ments in NGS technologies have occurred since this
project was carried out, including paired-end sequen-
cing, multiplexing and increased sequence output. The
study identified four HPV types not detected by com-
mercial assays namely HPV-30, 74, 86 and 90. The
prevalence of HPV 30, 74, 86 and 90 in 109 HIV positive
South African women were found by type-specific PCR
to be 14.6%, 12.8%, 4.6% and 8.3% respectively. As these
types were identified in a single specimen from an HIV
positive woman it is expected that there are many HPV
types not being detected in molecular epidemiologystudies using commercial kits. The significance of these
types in the context of their association to cervical dis-
ease remains to be investigated.
Methods
Study population and HPV status
The study participants (n = 109) were recruited from
women visiting an anti-retroviral (ARV) treatment clinic
in Cape Town, South Africa [13]. University of Cape
Town Health Sciences Faculty Research Ethics Commit-
tee approved the study (Reference 068/2005). Written
informed consent was given to take cervical samples for
HPV testing. All the women in the study were eighteen
years or older and the median age was 31 years (range
20–60 years). The women who were pregnant, had had a
hysterectomy or were menstruating at the time of re-
cruitment were excluded from the study. Pap smears
were taken using a cytobrush. An adequate pap smear
was obtained for 98/109 women, of which 65/98 (66.3%)
were abnormal. Atypical squamous cells of undeter-
mined significance (ASCUS) were identified in 15
(15.3%) of the women, low grade squamous intraepithe-
lial lesions (SILs) in 39 (40%), high-grade SILs in 10
(10.2%) and atypical squamous cells-cannot exclude
high-grade SIL in 1 (1.0%) [13]. Samples for HPV typing
were taken with a Digene cervical sampler (Gaithers-
burg, MD) and placed in Digene transport medium. The
samples were frozen until extracted for HPV DNA ana-
lysis using Roche Linear Array HPV Genotyping test
(LA) which can detect 37 HPV types. The number of
women positive on this test was 97/109. The most com-
mon HPV types were HPV 61 (24%), 66 (18%), 58 (17%),
53 (17%), 70 (16%) 45 (16%) and HPV 18 (16%) [13].
Among these, HPV types 66, 58, 45 and 18 are high-risk,
HPV-53 is a probable high-risk and HPV-61 and −70 are
low-risk types. One specimen, HH015, had 12 HPV
types detected by the LA and this specimen was selected
for Illumina sequencing.
DNA extraction and rolling circle amplification
Frozen cervical scrapings stored in Digene transport
medium (Qiagen, Gaithersburg, USA) were thawed and
total DNA extraction performed using the MagNA Pure
Compact Nucleic Acid Isolation Kit I (Roche Diagnos-
tics). HPV circular DNA was enriched for in the extract
from specimen HH015 by a RCA method with random
hexamer primers, using the IllustraTM TempliPhi kit
(Amersham Biosciences) as recommended by the
manufacturer.
Illumina sequencing and data analysis
The DNA from the RCA was fragmented at 32 psi of
pressure for 6 min. The fragments were purified using a
QIAquick PCR purification spin column (Qiagen,
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amplification on 1/8 of a flow cell using the Illumina
cluster generation kit v2, according to the manufac-
turer’s instructions. Single read sequencing was per-
formed using the Illumina sequencing kit v3 on an
Illumina Genome Analyzer II (GAII) system at the Uni-
versity of Western Cape (Cape Town, South Africa). Illu-
mina sequencing involves the large scale array of DNA
templates on a flow cell surface and parallel sequencing
of the templates by synthesis, using fluorescently labeled
nucleotides that act as reversible terminators during
each round of sequencing (http://www.illumina.com/
systems/genome_analyzer_iix/technology.ilmn).
The SSRs generated were evaluated with FASTQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and
trimmed for quality using FASTx-Toolkit (http://hannonlab.
cshl.edu/fastx_toolkit/index.html). Short sequence reads
were then de novo assembled using Velvet 0.7.31 [23]
and CLC Genomics Workbench4.6.1 (CLC bio, Aarhus,
Denmark). Velvet de novo assemblies were performed with
a hash length of 31, and a variety of parameters were
tested (expected coverage of 10, 100 or 1000, and coverage
cut-offs of 5, 10, or 100) to optimize assembly. Assembled
contigs over 100 bases were subjected to BLASTN and
BLASTX searches against the NCBI nt and nr databases,
respectively, using default parameters and an E value of
10-5. SSRs were also mapped against reference HPV
sequences obtained from the BLAST searches using CLC
Genomics Workbench 4.6.1 (CLC bio, Aarhus, Denmark.
Reference mapping was performed with strict mapping
settings (global alignment with a mismatch cost of 2 and
limit of 3 or 5).HPV type-specific PCR
In order to determine the prevalence of HPV types −30,
74, 86 and 90 in cervical specimens from the 109
women in our study population HPV-type specific PCR
was performed. Primers were designed to specifically tar-
get the E6/E7 genes from HPV types 30, 74, 86 and 90
(Table 4). PCR was performed in a 25 μl reaction volume
containing final concentrations of: 1X GoTaq DNA poly-
merase buffer (Promega, Madison, USA), 1 mM MgCl2,
200 μM of each dNTP, 0.65U GoTaq DNA polymerase
enzyme (Promega, Madison, USA), 0.4 μM of each pri-
mer and 2 μl DNA template. The MgCl2 concentration
was adjusted to 2 mM for the amplification of the type-
specific region of HPV-74. PCR cycling conditions were:
94°C for 10 minutes, 35 cycles consisting of 94°C for
40 seconds, 55°C for 40 seconds, 72°C for 40 seconds,
and a final hold at 72°C for 10 minutes. For the amplifi-
cation of the region of the E6 gene in HPV-86 and −90
the annealing temperatures were adjusted to 53 and
51.5°C, respectively, while the remaining cyclingconditions were kept the same. The amplified products
were electrophoreses on 2% agarose gels.
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